EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani OncBrothers: Practice-Changing Cancer Discussions 17:11 1 year ago 517 Скачать Далее
EMERALD Study lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Aditya Bardia OncBrothers: Practice-Changing Cancer Discussions 16:10 1 year ago 862 Скачать Далее
The Emerald Trial | Virginia Kaklamani, MD UT Health San Antonio MD Anderson Cancer Center 3:32 1 year ago 371 Скачать Далее
What EMERALD Phase III trial could mean for breast cancer patients | Virginia Kaklamani, MD UT Health San Antonio MD Anderson Cancer Center 1:01 1 year ago 403 Скачать Далее
Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC VJOncology 0:46 1 year ago 281 Скачать Далее
The impact of the EMERALD trial results based on duration of prior CDK4/6i in the metastatic setting VJOncology 0:30 1 year ago 120 Скачать Далее
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts ecancer 2:06 2 years ago 694 Скачать Далее
EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer VJOncology 1:27 2 years ago 749 Скачать Далее
Updated results by duration of prior CDK4/6i in the met setting of the Phase III EMERALD trial VJOncology 2:21 1 year ago 130 Скачать Далее
EMERALD Trial: An Analysis of Key Biomarkers and Patient Subgroups ReachMD 23:00 2 months ago 16 Скачать Далее
SABCS 2022丨Interview with Professor Virginia G. Kaklamani: Celebrating a Wonderful winter Symposium Oncology Frontier 8:54 1 year ago 31 Скачать Далее
New Breast Cancer Clinical Trial: Imlunestrant for Breast Cancer Power Life Sciences 1:11 1 year ago 145 Скачать Далее
Dr. Kaklamani Discusses Bone Health in Women With Breast Cancer Targeted Oncology 1:13 9 years ago 96 Скачать Далее
EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer VJOncology 2:03 2 years ago 1 638 Скачать Далее
FDA D.I.S.C.O. Burst Edition: FDA approves tebentafusp-tebn for unresectable or metastatic uveal ... U.S. Food and Drug Administration 4:01 3 months ago 16 Скачать Далее
Emerald™ Laser - Peace, Balance, Healing | Erchonia® Lasers Erchonia EMEA 1:20 4 years ago 598 Скачать Далее
Catherine Smith, MD, on the most common mutations associated with gilteritinib resistance OBRoncology 0:36 4 years ago 18 Скачать Далее
FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positi... U.S. Food and Drug Administration 4:01 3 months ago 38 Скачать Далее